REDWOOD CITY, Calif.--(BUSINESS WIRE)--Genelabs Technologies, Inc. (Nasdaq:GNLB) announced today that a presentation was made at the Inaugural HCV Drug Discovery meeting being held in La Jolla, California, providing information about Genelab’s first-in-class program targeting a novel antiviral mechanism for treating hepatitis C virus (HCV).
